CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.
Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...
In a cohort of more than 300 patients with relapsed or refractory disease, 99.1% treated with the CD19/CD22-directed product bicistronic achieved a complete remission or complete remission with ...
The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...